Cerberus Ventures' Chenny Zhang joined a TechBio investor panel at the LSX Investival Showcase in Miami alongside a group of fellow investors to discuss the new era of tech-driven biology.
Here is what stood out from the discussion.
The conditions have never been better. The cost, compute, and data conditions to start a TechBio company have never been more favorable, and founders who move now compound an advantage that only widens as the tooling matures.
AI is not a feature. It's the architecture. The leading companies aren't layering AI onto biology. They're building biology on top of AI, with data flywheels that become more defensible as foundation models in the space advance.
TechBio companies increasingly look like tech companies. Computation, automation, and robust data infrastructure are no longer differentiators. They are table stakes, and the gap between companies built this way from day one and those that did not is widening fast.
The industry has matured. Capital markets have not fully caught up. TechBio has evolved from early pilots and R&D collaborations to large-scale offtake agreements, but market appetite at the commercialization stage (Series A, Series B) remains inconsistent.
We believe the takeaway is clear. We’re at an inflection point in TechBio. The founders who move now will define the next generation of category-leading TechBio companies.
Suggested Reads
